TrialCancer medicine2023

Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study.

Alexander Lesokhin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.